From NIH National Cancer Institute Web Sites
- Approval of Osimertinib and Necitumumab Increases Lung Cancer Treatment Options
- Bringing Precision to Screening for Cancer
- Enhanced Risk-Based Lung Cancer Screening May Prevent More Deaths than Current Approaches
- FDA Approves Alectinib for ALK-Positive Non-Small Cell Lung Cancer
- Targeted Photoimmunotherapy Approach for Cancer Moves Forward
- Using Gene Expression to Diagnose Lung Cancer More Accurately
- With FDA Approval, Gefitinib Returns to U.S. Market for Some Patients with Lung Cancer
.png)
No hay comentarios:
Publicar un comentario